PharmAla Completes Shipment of LaNeo(TM) MDMA to Johns Hopkins

Executive Summary

• PharmAla Biotech completed shipment of its clinical‑grade LaNeo™ MDMA to Johns Hopkins University from a newly onboarded U.S. distribution site, enabling U.S. investigator‑sponsored trials.
• The company settled $150,000 of debt by issuing 1,666,667 common shares at a deemed price of $0.09 per share.

Key Details

• Product Shipment: LaNeo™ MDMA was successfully exported, cleared by state and federal regulators, and is now available for use in the continental United States.
• Recipient: Johns Hopkins University, a major U.S. research institution conducting investigator‑sponsored clinical trials on MDMA.
• Strategic Impact: The delivery addresses prior sourcing challenges for U.S. clinical investigators and supports PharmAla’s goal of expanding data on MDMA efficacy across multiple disorders.
• Debt Settlement: $150,000 owed to an arm‑length creditor was settled through the issuance of 1,666,667 common shares at a deemed price of $0.09 per share.
• Share Issuance Details: No cash proceeds; equity dilution of approximately 1.67 million shares to satisfy the debt obligation.

Notable Quotes

“Our delivery to Johns Hopkins represents a new day for MDMA research in the United States… ensuring a supply for PharmAla’s large and growing pool of Clinical Trial customers will ensure that data on MDMA’s efficacy … becomes widely available.” – Nick Kadysh, CEO, PharmAla Biotech

Materiality Assessment: Non‑Material – Positive (the update is operationally positive but does not constitute a material financial or strategic change).